Navigation Links
Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs)
Date:3/31/2011

SAN DIEGO, March 31, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) taking place in Orlando, Florida April 2-6, 2011. The poster presentations are based on studies utilizing Biocept's novel technology for the capture, detection, and analysis of circulating tumor cell (CTCs) in human clinical samples. This technology, Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) platform, enables not only CTC enumeration but also biomarker analysis as demonstrated in several of the posters. These data represent a broad scope of findings from studies involving blood and tumor samples from patients with breast, prostate, lung, colorectal, and ovarian cancers.

Farideh Bischoff, PhD, Director of Translational Research at Biocept, said, "In the poster presentations, data will be discussed that addresses our ability to detect CTCs that do not capture or stain with anti-EpCAM or anti-cytokeratin respectively which is the current method in the market.  Also, one of the poster presentations will cover the evaluation of HER2 gene amplification status by FISH (fluorescent in situ hybridization) in intact CTCs within a microfluidic channel.  Biocept's proprietary OncoCEE™ platform, which provides the ability to perform cytogenetic and molecular characterization of CTCs, may be an important clinically significant tool. We are excited to be developing innovative testing that may enable advances in the treatment of various cancers."  

Additional details for the AACR presentations are as follows:

Sun, Apr 3, 1:00 - 5:00 PM

319/12 - Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinoma Julie A. Mayer(1), Tam Pham(1), Karina Wong(1), Anthony Lucci(2), Farideh Bischoff(1), Savitri Krishnamurthy(2). (1)Biocept Inc., San Diego, CA; (2)The University of Texas MD Anderson Cancer Center, Houston, TX

Mon, Apr 4, 8:00 AM - 12:00 PM

1553/1 - Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs) Chad V. Pecot(1), Farideh Bischoff(2), Yvonne Lin(3), Padmavathi Jaladurgam(1), William Merritt(4), Tony Pircher(2), Steve Mikolajczyk(2), Julie Mayer(2), Karina Wong(2), Tam Pham(2), Justin Bottsford-Miller(1), Rebecca Stone(1), Joseph Celestino(1), Alpa Nick(1), Cathy Eng(1), Anil Sood(1). (1)UT M.D. Anderson Cancer Ctr., Houston, TX; (2)Biocept Incorporated, San Diego, CA; (3)University of Southern California, Los Angeles, CA; (4)South Carolina Oncology, Columbia, SC

Tue, Apr 5, 8:00 AM - 12:00 PM

LB-310/1 - FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform    

Julie A. Mayer, Tony J. Pircher, Stephen D. Mikolajczyk, Philip D. Cotter, Farideh Z. Bischoff. Biocept Inc, San Diego, CA

Wed, Apr 6, 8:00 AM - 12:00 PM

5172/13 - Fluorescence labeling of cytokeratin-negative circulating tumor cells in peripheral blood: A new paradigm for the study of cancer progression Stephen D. Mikolajczyk, Lisa S. Millar, Maryam Zomorrodi, Farideh Z. Bischoff, Jayne Scoggin, Tam Pham, Karina Wong, Tony J. Pircher. Biocept, Inc., San Diego, CA

The abstracts are available and can be viewed on-line at no charge through the AACR website at http://www.aacr.org, which is not part of this press release.

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced laboratory services company specializing in the capture, detection, isolation, and molecular analysis of Circulating Tumor Cells (CTCs).  Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services.   Biocept utilizes patented and innovative technologies to deliver clinically relevant and actionable information to physicians that enable better patient care.  This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.

About OncoCEE™

The OncoCEE™, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells, like CTCs, which may be present in only 1 of every 50-100 billion blood cells.  Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead on relying on traditional biopsy methods or surgical procedures.  Biocept differentiates the "liquid biopsy" CTC analysis by incorporating enhanced prognostic (CTC enumeration) and predictive bio-marker (ER, PR and HER2) information not currently offered by commercial laboratories or currently available technologies for breast cancer.  Existing methods to detect and enumerate circulating tumor cells (CTCs) rely only on the expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins without molecular bio-marker analysis.  This limited selection may exclude cells that have undergone intrinsic modifications of their phenotype such as epithelial/mesenchymal transition (EMT).   EMT may represent a possible explanation for all those patients who, despite an aggressive disease, are found negative for the presence of CTCs. OncoCEE™ has the potential to capture not only EpCAM but also mesenchymal-like cells.  Additionally, the OncoCEE™ enables in situ analysis of predictive biomarkers by ER, PR, and HER2.  HER2 status is predictive of a potential response to HER2 targeted agents such as tykerb and trastuzumab. Estrogen receptor (ER) and progesterone receptor (PR) status are important prognostic and predictive biomarkers in the treatment of breast cancer patients.  


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology
2. Biocept Announces Study to Isolate Circulating Tumor Cells from Blood
3. BioStorage Technologies Partners with AMDeC, LLC to Provide Tissue Storage and Cold Chain Logistics Services to Academic Medical Research Institutions
4. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
5. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
6. Applications Now Being Accepted for SBS 17th Annual Conference & Exhibition Academic Travel Awards
7. New Hope in Austin, Texas for Children Dealing with Social, Academic and Behavioral Issues; Austin Brain Balance Achievement Centers Grand Opening to Include Lectures for Parents, Teachers and Health Professionals
8. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
9. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
10. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
11. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- --> --> Transparency ... titled "Sports Medicine Devices Market - Global Industry Analysis, Size, ... the report, the global sports medicine devices market is anticipated ... growing from a value of US$6.1 bn in 2012 to ... --> The global sports medicine devices market is fueled ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric cardiovascular surgeons, cardiologists and ... making data on heart procedures public and easily understandable for families and patients ... of Pediatric and Congenital Heart Disease Outcomes will bring hundreds of pediatric heart ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... seeking candidates for the Board of Commissioners. Individuals interested in volunteer board service ... with diversity of clinical practice settings and across allied health to contribute to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, ... of 334 spine surgeons to know in 2016 . The list consists of ... of spine surgery. , Dr. Corenman understands the importance of clinical excellence; he ...
(Date:2/11/2016)... ... 2016 , ... The annual list showcases the 20 Most Promising SharePoint Solution ... dedication and commitment to the SharePoint ecosystem. A panel of experts and members of ... to recognize and promote technology entrepreneurship. , The survey was made at the ...
(Date:2/11/2016)... ... ... Husted Kicking has completed its Third Annual Husted Kicking College ... 2016 according to kicking coach Michael Husted. , “This event serves as an official ... Indianapolis,” says Husted. “The NFL uses a third party organization to select players for ...
Breaking Medicine News(10 mins):